

1 **TITLE**

2 Implementation of SARS-CoV-2 monoclonal antibody infusion sites at three medical centers in the  
3 United States: Strengths and challenges assessment to inform COVID-19 pandemic and future public  
4 health emergency use

5

6 **AUTHORS**

7 Anastasia S. Lambrou<sup>1,2</sup>, John T. Redd<sup>1</sup>, Miles A. Stewart<sup>1,2</sup>, Kaitlin Rainwater-Lovett<sup>1,2</sup>, Jonathan K.  
8 Thornhill<sup>1,2</sup>, Lynn Hayes<sup>1</sup>, Gina Smith<sup>1</sup>, George Thorp<sup>1</sup>, Christian Tomaszewski<sup>3,4</sup>, Adolphe Edward<sup>3,4</sup>,  
9 Natalia Elías Calles<sup>5</sup>, Mark Amox<sup>6</sup>, Steven Merta<sup>6</sup>, Tiffany Pfundt<sup>1</sup>, Victoria Callahan<sup>1</sup>, Adam Tewell<sup>1</sup>,  
10 Helga Scharf-Bell<sup>1</sup>, Samuel Imbriale<sup>1</sup>, Jeffrey D. Freeman<sup>1,2</sup>, Michael Anderson<sup>1</sup>, Robert P. Kadlec<sup>1</sup>

11

12 **AFFILIATIONS**

13 <sup>1</sup>Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and  
14 Human Services, Washington, DC, U.S.

15 <sup>2</sup>Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland, U.S.

16 <sup>3</sup>El Centro Regional Medical Center, El Centro, CA, U.S.

17 <sup>4</sup>UC San Diego Health, San Diego, CA, U.S.

18 <sup>5</sup>TMC HealthCare, Tucson, AZ, U.S.

19 <sup>6</sup>Sunrise Hospital and Medical Center, Las Vegas, NV, U.S.

20

21 **CORRESPONDING AUTHOR**

22 Anastasia S. Lambrou, PhD

23 Anastasia.Lambrou@hhs.gov

24

25 **SUPPLEMENTARY INFORMATION**

26 **SI Table 1.** Monoclonal antibody US Food and Drug Administration (FDA) Emergency Use Agreement EUA

27 prospective patient criteria as of February 2021.

Prospective Patient Age	Risk Factors
<p><b>≥18 years of age</b> and at least one of the following risk factors</p>	<ul style="list-style-type: none"> <li>• Have a body mass index (BMI) ≥35</li> <li>• Have chronic kidney disease</li> <li>• Have diabetes</li> <li>• Have immunosuppressive disease Are currently receiving immunosuppressive treatment</li> <li>• Are ≥65 years of age</li> </ul>
<p><b>≥55 years of age</b> and at least one of the following risk factors</p>	<ul style="list-style-type: none"> <li>• Cardiovascular disease</li> <li>• Hypertension</li> <li>• Chronic obstructive pulmonary disease/other chronic respiratory disease</li> </ul>
<p><b>12 – 17 years of age</b> and at least one of the following risk factors</p>	<ul style="list-style-type: none"> <li>• BMI ≥85th percentile for their age and gender based on CDC growth charts</li> <li>• Sickle cell disease</li> <li>• Congenital or acquired heart disease</li> <li>• Neurodevelopmental disorders, for example, cerebral palsy</li> <li>• Medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)</li> <li>• Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control</li> </ul>

28

29

30

31

32

33

34

35

36

37

38 **SI Table 2.** Monoclonal antibody infusion site process assessment metric descriptions and corresponding semi-  
 39 structured interview questions.

Metric	Definition	Data
<b>Engagement &amp; Workflow Logistics</b>	Components, steps, and official procedures of engaging with all stakeholders and the workflow of the infusion process to assess areas of improvement.	List the steps of the infusion process from recruitment to scheduling and receiving the therapy
		How long does each step take from the perspective of patients and staff?
		What are the current patient/community engagement/outreach mechanisms?
		What are the current provider/clinical engagement/outreach mechanisms?
		What forms of transportation do patients use to travel to and from their appointment?
		What barriers do patient face when scheduling or attending the appointment?
		How can the site increase provider/prescriber buy-in?
		What are the hard vs. soft constrains of the process?
<b>Timing</b>	Metrics related to timing of steps and engagement and therapy-quality related metrics such as preparation and temperature.	Time from registration/scheduling to appointment (mean, individual data if available)
		Time from symptom onset to infusion
		Time from positive test to infusion
		Total appointment time
		Estimated time for each infusion process step
		Transition time between patients/infusions
		Infusion site hours of operation
		Infusion site staff shift hours/timing
		List mAb therapy quality assurance process
		Pharmacist preparation timing and location
		Average amount of time between pharmacist preparation/cooling conditions to infusion
<b>Staffing</b>	Information on staff, their roles, and requirements to inform staffing models and process improvements.	List the number and types of workers maintaining the infusion site
		What is the level of training needed for specific infusion site workers?
		Is there a minimum staffing requirement?
		Is there a maximum number of individuals allowed in the space at once?
		What is the role of each type of worker?
		Can any worker take on multiple roles?
		How does process timing and steps change if the staff is down one nurse/physician/etc.?
		Which process steps are staff dependent?
		What is the most labor-intensive step for workers?
Which process step requires the most skills/training?		
<b>Physical Environment</b>	Information, layout, and interactions within the facilities/physical	Map infusion site and logistics environment
		Locations/direction of chairs/patients
		Dimensions of infusion site

	environment in the infusion site to inform process improvements and prototype set-ups.	Infection control/distancing in physical environment
		Can the size or shape of the space be altered?
		Is any daily setup or deconstruction required?
<b>Resources</b>	All resources needed that are not staff to inform process model, scale-up, and process improvements.	List all physical resources needed for the infusion process
		PPE resources needed
		Infusion site/tent resources
		Information systems resources
		Could the patient be observed in another setting, i.e., car? What parts of the process do not have to occur in the tent/site?
<b>Monitoring &amp; Resilience</b>	Flexibility and resilience of system to process disturbances, emergencies, and capacity changes.	What happens if an emergency/adverse event occurs?
		How common are emergency/adverse events and how do they impact staffing/flow/etc.?
		What happens if a patient does not show up for their appointment?
		How common are "no shows" and how do they impact staffing/flow/etc.?
		Describe the system that is currently being used for patient scheduling
		Describe the system currently used to monitor and evaluate (M&E) the infusion process
		Describe the system that is currently being used to
		Describe the system that is currently being used to monitor logistics and resource allocation

40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51

52

53

54

55

56

57

58



59 **SI Figure 1.** External physical environments of the temporary tent monoclonal antibody infusion sites.

60

61

62

63

64

65



66

67

68

69

70

71

72



73 **SI Figure 2.** Examples of the internal physical environments of the three monoclonal antibody infusion sites

74 exhibiting both open-concept and individual patient room layouts for the infusion process